Savara (NASDAQ:SVRA – Get Free Report) released its earnings results on Thursday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02), Zacks reports. The company had revenue of $0.27 million for the quarter.
Savara Stock Up 4.7 %
Shares of Savara stock opened at $2.91 on Friday. Savara has a twelve month low of $2.26 and a twelve month high of $5.34. The stock has a market cap of $499.41 million, a price-to-earnings ratio of -6.77 and a beta of 0.60. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. The company has a fifty day moving average price of $2.72 and a 200 day moving average price of $3.26.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on SVRA shares. JMP Securities reiterated a “market outperform” rating and issued a $9.00 price target on shares of Savara in a report on Thursday, December 19th. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Savara in a report on Friday. Finally, Wells Fargo & Company started coverage on Savara in a research note on Friday, December 20th. They set an “overweight” rating and a $8.00 price target for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Savara presently has an average rating of “Moderate Buy” and an average target price of $8.83.
About Savara
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Stories
- Five stocks we like better than Savara
- What is a Death Cross in Stocks?
- MarketBeat Week in Review – 03/24 – 03/28
- What Are Dividends? Buy the Best Dividend Stocks
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- Using the MarketBeat Dividend Yield Calculator
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.
